[Insert Logo]

Journal of Osteopathic Medicine March 2024: The role of aspirin, statins, colchicine, and IL-1 inhibitors in prevention of cardiovascular events: a systematic integrative review

OVERVIEW:

Literature describing the integration of osteopathic manipulative treatment (OMT) during prenatal care visits in a resident clinic setting are scarce. Concise and readily accessible resources reviewing OMT in pregnancy are limited. Musculoskeletal (MSK) pain in pregnancy is common. Specifically, low back pain (LBP) often accompanies pregnancy and may negatively impact sleep, the ability to work, and the ability to complete daily tasks. Treatment options for LBP in pregnancy are limited due to the concern for fetal or maternal harm associated with pharmacologic options or invasive procedures. OMT is a low-risk intervention that has been demonstrated to improve back pain and reduce deterioration of back-specific function in pregnancy. OMT provides pregnant patients with additional treatment options and relief from MSK pain. This may reduce the number of patients with untreated MSK pain and benefit those who are unable to attend additional appointments outside of prenatal care due to financial or logistic barriers. OMT can be integrated into routine prenatal care visits in a training setting by providing complaint-specific OMT and determining how treatments can be performed for each unique examination room and table. Reviewing OMT in pregnancy with the attending physician prior to treatment, contraindications to OMT in pregnancy, and visualizing how treatments will be altered in pregnancy allows for smooth integration.

Authors: Vania Arboleda; Ashley Hackworth, MS; Sabrina Bonnice; Vivianne Gonzalez, MS; Dominick Cabrera, MS; Craig Colletti; Courtney Baxter; Claudia Aleman Oliva; Shadman Kabir; Jing Huang; Ashar Khan; Stefanie Filoramo, MS; Sara Ecoff, MS; Michelle Demory Beckler, PhD; Marc M. Kesselman, DO

OBJECTIVES:

 Outline the current recommendations for cardiovascular disease prevention

 Describe the role of the studied drugs in prevention of primary cardiovascular disease events

 Describe the role of the studied drugs in prevention of secondary cardiovascular disease events

Expiration Date:  February 28, 2027

The AOA designates this activity for a maximum of 1.0 AOA Category 1-B Credit. Physicians should claim only the credit commensurate with the extent of their participation in the activity.